LICENSE AGREEMENTLicense Agreement • November 7th, 2017 • Exicure, Inc. • Pharmaceutical preparations • Illinois
This Agreement is made with effect from June 17th, 2016 (the “Effective Date”), by and between Northwestern University, an Illinois not-for-profit corporation with a principal place of business at 633 Clark Street, Evanston, Illinois 60208 (“Northwestern”) and Exicure Inc., a Delaware corporation, with a principal place of business at 8045 Lamon Avenue, Suite 410, Skokie, IL 60077 (“Licensee”).
RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT by and between EXICURE, INC. and PURDUE PHARMA L.P.Research Collaboration, Option and License Agreement • November 7th, 2017 • Exicure, Inc. • Pharmaceutical preparations • New York
This RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of December 2nd, 2016 (the “Effective Date”) by and between EXICURE, INC., a Delaware corporation having an address at 8045 Lamon Ave, Skokie, Illinois 60077, United States of America (“Licensor”), and PURDUE PHARMA L.P., a Delaware limited partnership having an address at One Stamford Forum, 201 Tresser Boulevard, Stamford, Connecticut 06901, United States of America (“Licensee”). Licensor and Licensee are sometimes referred to individually as a “Party” and collectively as the “Parties.”
RESTATED LICENSE AGREEMENTLicense Agreement • November 7th, 2017 • Exicure, Inc. • Pharmaceutical preparations • Illinois
This Restated License Agreement (“Agreement”) made this 15th day of August, 2015, and is effective as of December 12, 2011 (the “Effective Date”), by and between Northwestern University, an Illinois not-for-profit corporation with a principal place of business at 633 Clark Street, Evanston, Illinois 60208 (hereinafter referred to as “Northwestern”) and Exicure, Inc., with a principal place of business at 8045 Lamon Avenue, Suite 410, Skokie, IL 60077 (hereinafter referred to as “Licensee”), formerly known as AuraSense Therapeutics, LLC and AuraSense Therapeutics, Inc.
Re: Side Agreement to “Northwestern Agreements” in Relation to Purdue SublicenseSide Agreement • November 7th, 2017 • Exicure, Inc. • Pharmaceutical preparations
Reference is hereby made to that certain License Agreement executed on February 10, 2016 and effective as of May 27, 2014, to that certain License Agreement executed and effective on June 17, 2016, and that certain Restated License Agreement amended on September 27, 2016 and effective as of December 12, 2011 (collectively, the “Northwestern Agreements”) by and between Northwestern University, an Illinois not-for-profit corporation with a principal place of business at 633 Clark Street, Evanston, Illinois, 60208 (“Northwestern”), and Exicure, Inc., a Delaware corporation with a principal place of business at 8045 Lamon Avenue, Skokie, Illinois, 60077 (“Exicure”).
THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL...License Agreement • November 7th, 2017 • Exicure, Inc. • Pharmaceutical preparations
NORTHWESTERN UNIVERSITY EXICURE, INC. /s/ Alicia Löffler, Ph.D. /s/ David A. Giljohann, Ph.D. Alicia Löffler, Ph.D. David A. Giljohann, Ph.D. Associate Vice President for Research,and Executive Director, INVO Chief Executive Officer
